| scholarly article | Q13442814 |
| P50 | author | Lutz Klinghammer | Q43174812 |
| P2093 | author name string | J Ludwig | |
| A Schmidt | |||
| M Herrmann | |||
| W G Daniel | |||
| A Schmeisser | |||
| C D Garlichs | |||
| D Raaz | |||
| S Eskafi | |||
| P2860 | cites work | CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells | Q24310570 |
| Reduction of atherosclerosis in mice by inhibition of CD40 signalling | Q24316540 | ||
| Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help) | Q24675460 | ||
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| The soluble CD40 ligand sCD154 in systemic lupus erythematosus | Q33858548 | ||
| A classification of unstable angina revisited | Q33958256 | ||
| CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. | Q34324146 | ||
| CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. | Q34721501 | ||
| Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice | Q35160907 | ||
| Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype | Q35161070 | ||
| Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis | Q36028683 | ||
| Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system | Q36216095 | ||
| Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous T | Q39486711 | ||
| Recombinant soluble trimeric CD40 ligand is biologically active | Q41357988 | ||
| Induction of human IgE synthesis in B cells by mast cells and basophils | Q41526881 | ||
| Expression of functional CD40 by vascular endothelial cells | Q41981036 | ||
| CD40 signaling in vascular cells: a key role in atherosclerosis? | Q47726341 | ||
| Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. | Q52526594 | ||
| Requirement for CD154 in the progression of atherosclerosis. | Q52536870 | ||
| Increasing Levels of Interleukin (IL)-1Ra and IL-6 During the First 2 Days of Hospitalization in Unstable Angina Are Associated With Increased Risk of In-Hospital Coronary Events | Q58230314 | ||
| Elevated Levels of Interleukin-6 in Unstable Angina | Q58230354 | ||
| Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40 | Q62604578 | ||
| Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry | Q68160190 | ||
| Platelet activation in unstable coronary disease | Q68903080 | ||
| Increased neutrophil-platelet adhesion in patients with unstable angina | Q71571191 | ||
| Increased soluble form of P-selectin in patients with unstable angina | Q71709857 | ||
| Agglutination of isolated platelet membranes | Q71883067 | ||
| Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease | Q72227001 | ||
| Acute T-cell activation is detectable in unstable angina | Q73233066 | ||
| CD40L activation in circulating platelets in patients with acute coronary syndrome | Q73368214 | ||
| CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets | Q73386215 | ||
| CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression | Q74310001 | ||
| Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes | Q78108701 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | acute coronary syndrome | Q266018 |
| P304 | page(s) | 649-655 | |
| P577 | publication date | 2001-12-01 | |
| P1433 | published in | Heart | Q856338 |
| P1476 | title | Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets | |
| P478 | volume | 86 |
| Q35596004 | Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients |
| Q91928779 | Association between the No-Reflow Phenomenon and Soluble CD40 Ligand Level in Patients with Acute ST-Segment Elevation Myocardial Infarction |
| Q83921113 | Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients |
| Q36333917 | Biomarkers in acute coronary syndromes and their role in diabetic patients |
| Q37500635 | Biomarkers in cardiovascular medicine |
| Q93355469 | Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis |
| Q40071909 | CCL3 (MIP-1 alpha) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events |
| Q26752784 | CD40 in coronary artery disease: a matter of macrophages? |
| Q35848866 | CD40 ligand: a novel target in the fight against cardiovascular disease |
| Q38042321 | CD40-CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications |
| Q90669240 | CD40L Priming of Platelets via NF-κB Activation is CD40- and TAK1-Dependent |
| Q33814059 | CD40L and Its Receptors in Atherothrombosis-An Update |
| Q43098741 | Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel |
| Q33646945 | Circulating soluble CD40 ligand mediates the interaction between neutrophils and platelets in acute coronary syndrome |
| Q28218124 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease |
| Q36948507 | Developmental changes in soluble CD40 ligand |
| Q46372426 | Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients |
| Q28166019 | Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure |
| Q43227478 | Expression of EMMPRIN (CD147) on circulating platelets in vivo. |
| Q33435650 | Flow Cytometric Investigation of Classical and Alternative Platelet Activation Markers |
| Q57718046 | Increased concentrations of soluble CD40 ligand may help to identify type 1 diabetic adolescents and young adults at risk for developing persistent microalbuminuria |
| Q28167456 | Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke |
| Q35795328 | Individualizing therapy in acute coronary syndromes: using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy |
| Q79259689 | Inhibition of platelet aggregation by nitric oxide donors improves with rest |
| Q51959245 | Inverse correlation between soluble CD40 ligand and soluble CD40 is absent in patients with unstable angina. |
| Q48033874 | Markers of thrombosis and hemostasis in acute coronary syndromes: relationship to increased heart rate and reduced heart-rate variability. |
| Q36171374 | Novel uses for anti-platelet agents as anti-inflammatory drugs. |
| Q53704529 | Platelet CD40 contributes to enhanced monocyte chemoattractant protein 1 levels in patients with resistant hypertension. |
| Q49082878 | Platelet and monocyte activation in acute ischemic stroke--is there a correlation with stroke etiology? |
| Q53120736 | Platelet count predicts cardiovascular mortality in very elderly patients with myocardial infarction. |
| Q37658732 | Platelet hyperfunction as risk factor for chronic and acute coronary events |
| Q37207078 | Platelet reactivity and the identification of acute coronary syndromes in the emergency department |
| Q73351358 | Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients |
| Q34779205 | Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count |
| Q44283435 | Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy |
| Q36350146 | Soluble CD40 ligand induces β 3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling |
| Q83857055 | Soluble CD40 ligand levels in acute pulmonary embolism: a prospective, randomized, controlled study |
| Q37829738 | The CD40-CD40L system in cardiovascular disease. |
| Q28165330 | The central role of platelet activation in determining the severity of acute coronary syndromes |
| Q34020389 | The levels of soluble CD40 ligand and C-reactive protein in normal weight, overweight and obese people |
| Q35106421 | The roles of buyang huanwu decoction in anti-inflammation, antioxidation and regulation of lipid metabolism in rats with myocardial ischemia |
| Q40361542 | The tumor necrosis factor superfamily in heart failure |
| Q40393639 | The use of MCP-1 and soluble CD40 ligand in a pathophysiology-guided approach to the management of coronary artery disease |
| Q34407458 | Vascular Effects of Ultrafine Particles in Persons with Type 2 Diabetes |
| Q54539813 | β1-Adrenoceptor antibody-induced increase in soluble CD40 ligand release in chronic periodontitis patients: role of prostaglandin E(2). |
Search more.